Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo
Phase 2/3Active 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate-to-severe Chronic Plaque Psoriasis
Conditions
Moderate-to-severe Chronic Plaque Psoriasis
Trial Timeline
Jan 15, 2020 → Aug 5, 2031
NCT ID
NCT03997786About Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo is a phase 2/3 stage product being developed by Sun Pharmaceutical for Moderate-to-severe Chronic Plaque Psoriasis. The current trial status is active. This product is registered under clinical trial identifier NCT03997786. Target conditions include Moderate-to-severe Chronic Plaque Psoriasis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03997786 | Phase 2/3 | Active |
Competing Products
13 competing products in Moderate-to-severe Chronic Plaque Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine | Pacira Biosciences | Approved | 80 |
| SHR-1314 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR-1314 + Placebo | Jiangsu Hengrui Medicine | Phase 1/2 | 41 |
| SHR-1314 + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Indacaterol + Control | Novartis | Phase 3 | 77 |
| Deucravacitinib | Bristol Myers Squibb | Pre-clinical | 22 |
| Dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| dupilumab | Sanofi | Approved | 84 |
| dupilumab | Sanofi | Pre-clinical | 22 |
| Ponesimod | Vanda Pharmaceuticals | Phase 3 | 69 |
| sufentanil sublingual tablet 30 mcg | Talphera | Phase 3 | 69 |
| Zalviso™ 15 mcg | Talphera | Phase 3 | 69 |
| sufentanil sublingual 30 mcg tablet | Talphera | Phase 3 | 69 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85